Evidence map›Paper›PMID 41096863›Full record

ArticleInternational journal of molecular sciences2025

Co-Targeting PD-1 and IL-33/ST2 Pathways for Enhanced Acquired Anti-Tumor Immunity in Breast Cancer.

Marina Z Jovanović, Milena Jurišević, Milan Jovanović, Nevena Gajović, Miodrag Jocić, Marina M Jovanović, Boško Milev, Krstina Doklestić Vasiljev, Ivan Jovanović

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marina Z JovanovićCenter for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
Milena JuriševićCenter for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
Milan JovanovićDepartment of Abdominal Surgery, Military Medical Academy, 11000 Belgrade, Serbia.
Nevena GajovićCenter for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
Miodrag JocićMedical Faculty of the Military Medical Academy, University of Defense, 11000 Belgrade, Serbia.ORCID 0000-0002-1704-4208
Marina M JovanovićDepartment of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.ORCID 0000-0002-7691-6133
Boško MilevDepartment of Abdominal Surgery, Military Medical Academy, 11000 Belgrade, Serbia.
Krstina Doklestić VasiljevFaculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Ivan JovanovićCenter for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.ORCID 0000-0002-1169-2378

Funding

Medical faculty of Military Medical Academy MF MMA 03/22-24Ministry of Science, Technological Development and Innovation, Republic of Serbia under Grant Agreements with University of Kragujevac-Faculty of Medical Sciences 451-03-137/2025-03/200111
6 · The paper itself

Abstract

Despite advances in immunotherapy, the treatment of breast cancer still remains a major global problem. In a previous study, we showed that co-blockade of Interleukin-33/ST2 and Programmed death-1/Programmed death-ligand (PD-1/PD-L) signaling pathways strongly slows progression by enhancing the antitumor capacity of natural killer (NK) cells. The main aim of this study is to elucidate the exact effect of co-blockade on the T lymphocyte and macrophage effector cells. 4T1 cells were used to induct breast cancer in female BALB/C and BALB/C ST2

Indexed as

Antineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsInterleukin-1 Receptor-Like 1 ProteinInterleukin-33Mammary Neoplasms, ExperimentalProgrammed Cell Death 1 ReceptorAnimalsCell Line, TumorFemaleMacrophagesMiceMice, Inbred BALB CMice, KnockoutSignal TransductionT-LymphocytesTumor MicroenvironmentAntineoplastic Agents, ImmunologicalIl1rl1 protein, mouseIl33 protein, mouseInterleukin-1 Receptor-Like 1 ProteinInterleukin-33Pdcd1 protein, mouseProgrammed Cell Death 1 Receptoranti-PD-1breast cancerIL-33macrophagesT cells

Identifiers

PMID41096863
PMCPMC12525228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.